<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845179</url>
  </required_header>
  <id_info>
    <org_study_id>H-18040916</org_study_id>
    <nct_id>NCT03845179</nct_id>
  </id_info>
  <brief_title>GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide</brief_title>
  <official_title>The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if the effect of DPP-4 inhibitors is mediated in part by
      Glucose-dependent insulinotropic polypeptide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate
      the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, cross-over.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded study. Both participants and investigators are blinded to interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of C-peptide during GIP receptor antagonism compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of plasma glucose during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of insulin during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and intact GIP</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of total and intact GIP during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and intact GLP-1</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of total and intact GLP-1 during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of glucagon during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of CTX during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>5 hours</time_frame>
    <description>Concentrations of lipids during GIP receptor antagonism compared to placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gallbladder volume</measure>
    <time_frame>5 hours</time_frame>
    <description>Measures from ultrasound sonography</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>5 hours</time_frame>
    <description>Repeated measures</description>
  </other_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>5 hours</time_frame>
    <description>Repeated measures</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline infusion</description>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP receptor antagonist</intervention_name>
    <description>Used for infusion on study days</description>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitor</intervention_name>
    <description>Oral administration of DPP-4 inhibitor in active treatment period</description>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Oral administration of placebo tablet in placebo treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes, treatment: lifestyle changes or metformin

          -  HbA1c &lt; 75 mmol/mol

        Exclusion Criteria:

          -  diagnosed liver disease

          -  eGFR &lt; 60 ml/min/1,73m2

          -  NYHA III or IV

          -  anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Signe Stensen, MD</last_name>
    <phone>+45 3867 3171</phone>
    <email>signe.stensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K Knop, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research</name>
      <address>
        <city>Copenhagen</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Signe Stensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

